Integrated Filing — IndAS



General information about company
Scrip Code 532649
NSE Symbol NECLIFE
MSEI Symbol NOTLISTED
ISIN INE023H01027
Name of company Nectar Lifesciences Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 07-Jul-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 03-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceutical Business Segment.
Start date and time of board meeting 07-Jul-2025   19:40:00
End date and time of board meeting 07-Jul-2025   22:10:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2024-08-14
Indicate Company website link for updated RPT policy of the Company www.neclife.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There is no default by the Company on its loans. The Company has not issued any debt securities.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 4306946000 16730743000
Other income 777000 18909000
Total income 4307723000 16749652000
2 Expenses
(a) Cost of materials consumed 4056989000 12507226000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 968840000 1172869000
(d) Employee benefit expense 238070000 964746000
(e) Finance costs 176720000 745783000
(f) Depreciation, depletion and amortisation expense 157669000 623894000
(f) Other Expenses
1 Other Expenses 586085000 2350474000
Total other expenses 586085000 2350474000
Total expenses 6184373000 18364992000
3 Total profit before exceptional items and tax -1876650000 -1615340000
4 Exceptional items 0 0
5 Total profit before tax -1876650000 -1615340000
6 Tax expense
7 Current tax 0 0
8 Deferred tax -575758000 -478532000
9 Total tax expenses -575758000 -478532000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations -1300892000 -1136808000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period -1300892000 -1136808000
17 Other comprehensive income net of taxes 5398000 5398000
18 Total Comprehensive Income for the period -1295494000 -1131410000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 224261000 224261000
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 9336873000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -5.8 -5.07
Diluted earnings (loss) per share from continuing operations -5.8 -5.07
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -5.8 -5.07
Diluted earnings (loss) per share from continuing and discontinued operations -5.8 -5.07
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) Notes: n n1. The above financial results were reviewed by Audit Committee on July 7, 2025 and approved by the Board in its meeting held on July 7, 2025 and further Audited by the Statutory Auditors of the Company. The auditor's report is attached alongwith these results. The Board of Directors hereby declare that audit reports do not contain any modified opinion. n n2.The company is exclusively in the pharmaceutical business segment. n n3. Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period. n n4.The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figure in respect of the full financial year ended March 31 and the unaudited published year to date figures upto the third quarter ended December 31 which was subject to limited review. n n5.The Company Nectar Lifesciences Limited is Not a Large Corporate as per the framework provided in the SEBI Circular dated October 19, 2023 on Fund raising by issuance of debt securities by Large Entities. n n6. During the financial year 2020-21, the company engaged an independent technical expert nominated by the Lead Bank under the Agency for Special Monitoring to perform a comprehensive quality assessment of certain raw materials and work in progress batches. Based on expert’s findings, the Company reclassified inventory totaling Rs. 25,108.73 lakhs from inventories current to Non- Current Assets. n nNotwithstanding the reports furnished by technical expert about the remaining non-current inventory, the management has, adhering to conservatism principle, decided to mark down the realizable value of inventory to Rs. 5,061.27 lakhs from Rs.17,733.10 lakhs, based on the fact that the inventory has been in stocks for a considerable period. The resultant loss has been charged to profit and loss account in the fourth quarter. The management is confident that the value remaining after mark down is realizable. n nThe classification and measurement of net realizable value reflect significant management judgements and estimates concerning market demand, processing yields and future selling prices. These estimates are inherently uncertain and actual outcome may differ. Accordingly, the company periodically reviews and adjusts carrying amounts as warranted by changing conditions. n n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 5766046000
Capital work-in-progress 567283000
Investment property
Goodwill 0
Other intangible assets 565043000
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 2431000
Trade receivables, non-current 84871000
Loans, non-current 0
Other non-current financial assets 32512000
Total non-current financial assets 119814000
Deferred tax assets (net) 550415000
Other non-current assets 527862000
Total non-current assets 8096463000
2 Current assets
Inventories 6901596000
Current financial asset
Current investments 5295000
Trade receivables, current 3454847000
Cash and cash equivalents 192197000
Bank balance other than cash and cash equivalents 0
Loans, current 8569000
Other current financial assets 75122000
Total current financial assets 3736030000
Current tax assets (net)
Other current assets 1738224000
Total current assets 12375850000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 20472313000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 224261000
Other equity 9336873000
Total equity attributable to owners of parent 9561134000
Non controlling interest
Total equity 9561134000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 601273000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
Total non-current financial liabilities 601273000
Provisions, non-current 87284000
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities 7208000
Total non-current liabilities 695765000
Current liabilities
Current financial liabilities
Borrowings, current 5218954000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 87554000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 4293608000
Total Trade payable 4381162000
Other current financial liabilities 497727000
Total current financial liabilities 10097843000
Other current liabilities 88350000
Provisions, current 29221000
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 10215414000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 10911179000
Total equity and liabilites 20472313000
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block
Textual Information(1) Note: n n1) The Other non-current assets of Rs.5278.62 Lacs includes the Non Current Inventory of Rs.5061.27 Lacs. n n2) Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of the net defined benefit liability/asset (Net of Tax) 5398000 5398000
Total Amount of items that will not be reclassified to profit and loss 5398000 5398000
2 Income tax relating to items that will not be reclassified to profit or loss 0 0
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 5398000 5398000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax -1615340000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 745783000
Adjustments for decrease (increase) in inventories 1463209000
Adjustments for decrease (increase) in trade receivables, current 337088000
Adjustments for decrease (increase) in trade receivables, non-current -2330000
Adjustments for decrease (increase) in other current assets -87793000
Adjustments for decrease (increase) in other non-current assets -557000
Adjustments for other financial assets, non-current -4086000
Adjustments for other financial assets, current 667000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 184551000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -81415000
Adjustments for increase (decrease) in other non-current liabilities -250000
Adjustments for depreciation and amortisation expense 623894000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 7007000
Adjustments for provisions, non-current 7915000
Adjustments for other financial liabilities, current 110423000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 18561000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow -205000
Other adjustments to reconcile profit (loss) 8298000
Other adjustments for non-cash items 16081000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 3309719000
Net cash flows from (used in) operations 1694379000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 1694379000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 83000
Purchase of property, plant and equipment 437948000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 14894000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 3667000
Net cash flows from (used in) investing activities -419304000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 532807000
Payments of lease liabilities 2330000
Dividends paid 0
Interest paid 745783000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -1280920000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -5845000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -5845000
Cash and cash equivalents cash flow statement at beginning of period 0
Cash and cash equivalents cash flow statement at end of period -5845000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deepak Jindal & Co. Yes 31-May-2027


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Nectar Lifesciences Limited Mr. Sanjiv Goyal Chairman and Managing Director Remuneration Audit Committee approval has been received at the time of appointment and revision in remuneration. No Special Remarks 10810000 939000 10065000 Textual Information(1)
2 Nectar Lifesciences Limited Nectar Lifesciences Charitable Foundation Promoter or Director and KMPs have significant Influence Any other transaction CSR Expenses One time aapproval has been taken from Audit Committee. No Special Remarks 1324000 0 0 Textual Information(2)
3 Nectar Lifesciences Limited Sanjiv HUF Promoter or Director have significantnInfluence Loan Not Applicable 0 100000000 100000000 Loan 0 No tenure Textual Information(3)
4 Nectar Lifesciences Limited Mr. Sanjiv Goyal Chairman and Managing Director Loan Not Applicable 0 30000000 30000000 Loan 0 No tenure Textual Information(4)
5 Nectar Lifesciences Limited Mr. Sanjiv Goyal Chairman and Managing Director Loan No 0 7500000 7550000 Loan 0.09 2 Years Textual Information(5)
6 Nectar Lifesciences Limited Mr. Sanjiv Goyal Chairman and Managing Director Interest received No 337000 386000 0
7 Nectar Lifesciences Limited Mr. Sushil Kapoor Chief Financial Officer Any other transaction Security against Car No 0 348000 348000 Textual Information(6)
8 Nectar Lifesciences Limited Mrs. Raman Goyal Relative of Chairman and Managing Director Purchase of goods or services No 4200000 0 0
Total value of transaction during the reporting period 16671000



Text Block
Textual Information(1) Audit Committee approval has been received on all prepertual transactions for the term of Managerial Remuneration or Salary to KMPs or Sitting Fee or CSR Expenditure. Further approvals from Board or members have been received as per the Companies Act, 2013
Textual Information(2) Audit Committee approval has been received on all prepertual transactions for the term of Managerial Remuneration or Salary to KMPs or Sitting Fee or CSR Expenditure. Further approvals from Board or members have been received as per the Companies Act, 2013
Textual Information(3) Unsecured Interest free loan received as an obligation from the promoter as per the One time restructuring with Banks in FY 2021-22, already approved by the Board of Directors. There is no resource has been transferred or proposed to be transferred from the Company.
Textual Information(4) Unsecured Interest free loan received as an obligation from the promoter as per the One time restructuring with Banks in FY 2021-22, already approved by the Board of Directors. There is no resource has been transferred or proposed to be transferred from the Company.
Textual Information(5) 1. The advance or loan is provided as per Advance Policy of the Company applicable to all employees. 2.The Loan Amount is lein against retirement benefits of Chairman and Managing Director of the Company.
Textual Information(6) Security Received as a part of conditions of service